Rexahn enters trial collaboration with Merck for breast cancer tx
Merck & Co. Inc. and Rexahn Pharmaceuticals Inc. penned an agreement to study the combination of Rexahn’s RX5902 (supinoxin) with Merck’s Keytruda (pembrolizumab) as a potential therapy for metastatic triple negative breast cancer (TNBC).
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.